Drug Profile
Research programme: scleroderma therapeutics - BioFocus/Biogen
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator BioFocus DPI
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Scleroderma
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Scleroderma in United Kingdom
- 31 Mar 2014 BioFocus has been acquired by Charles River Laboratories
- 12 Nov 2013 Early research in Scleroderma in United Kingdom (unspecified route)